Terpa Sp. z o.o. sp.k.

Lublin 12 trials 3 recruiting

12 Registered trials

3 Currently recruiting

Organisation

Terpa Sp. z o.o. sp.k.

Location

Lublin, Poland

Identifier

ORG-100043613

Address

Ul. Pogodna 34, 20-337, Poland

Departments

Gabinety TERPA
N/A
NA
No Department

Clinical trials at this site (12)

Search interface

A Phase III, randomized, controlled study of furazidin for bacterial vaginosis. Recruiting

2024-515332-80-00 Bacterial vaginosis 5 2026-02-23
A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes Recruiting

2025-523260-20-00 type 2 diabetes 4 2026-04-28
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting

2025-523657-34-00 Obesity 5 2026-04-13
Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended

2024-519530-24-00 Overweight and obesity 5 2025-10-31
A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn… Ended

2024-510846-15-00 Chronic Kidney Disease, with or without Type 2 diabetes 4 2025-04-14
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended

2024-511450-49-00 Obesity 5 2024-10-22
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended

2023-503657-35-00 Obesity 5 2023-10-10
A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended

2023-506931-13-00 Overweight and obesity and type 2 diabetes 5 2023-01-30
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain ( TRIUMPH-7 ) Ended

2024-517431-43-00 Overweight 5